Therefore, we continued to verify the role of GPER1 in NAFLD pathogenesis by treating female mice with GPER1-specific agonist G1 rather than constructing GPER1 hepatocyte-specific transgenic (GPER1-HTG) mice in response to HFD feeding for 24 weeks (Fig. S8A) or HFHC diet feeding for 20 weeks (Fig. S9A). The gene discussed is GPER1; the disease is metabolic dysfunction-associated steatotic liver disease.